Skip to content

Clinical study on traditional Chinese medicine for the treatment of gastric cancer with blood hypercoagulability

Clinical study on traditional Chinese medicine for the treatment of gastric cancer with blood hypercoagulability

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003603
Enrollment
Unknown
Registered
2013-07-22
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

treatment group:Modified Liangfu granules + The basic treatment of conventional medicine

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Have all of the following eight criteria: 1. Conform to the diagnosis of gastric cancer and TNM stage III-IV stage; 2. Accord with diagnostic criteria proposed about blood hypercoagulability; 3. In accordance with the standards of syndrome differentiation on deficient cold of spleen and stomach, and Qi-deficiency-blood-stasis; 4. Aged between 18 and 80 years old; 5. Stop antiplatelet, anticoagulation, thrombolysis fails and chinese medecine of promoting blood circulation for removing blood stasis therapy at least one month before the study; 6. No serious diseases of heart, liver, kidney, brain, blood and other systems; 7. The general situation is good, performance status (KPS) score above 60 points, the expected survival time >=3 months; 8. Volunteers, and signed the informed consent.

Exclusion criteria

Exclusion criteria: Have any one of the following items: 1. Not meet the above inclusion criteria; 2. A bleeding tendency or accompanied with visceral hemorrhage; 3. Pregnant women and mental patients; 4. Unable to follow the prescription; 5. The patient is forced to interrupt treatment because of severe side effects during the treatment.

Design outcomes

Primary

MeasureTime frame
Prothrombin time;Prothrombin ratio;Prothrombin percent activity;INR;Activated partial prothrombin time, APPT;Content of fibrinogen;Thrombin clotting time;D two dimer;Symptoms and signs;Thrombotic event;

Secondary

MeasureTime frame
White blood cell;Red blood cell;Hemoglobin;Platelet;Quality of life;

Countries

China

Contacts

Public ContactXinyi Chen

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

chenxinyi0729@126.com+86 010 84013127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026